The iShares Neuroscience and Healthcare ETF (IBRN) offers targeted exposure to companies poised to benefit from advancements in neuroscience. With an expense ratio of 0.47%, IBRN provides access to a concentrated portfolio of 57 U.S. and non-U.S. companies. The fund has approximately $0.00B in assets under management and focuses exclusively on the healthcare sector, differentiating it from broader healthcare ETFs. Past performance does not guarantee future results.
The iShares Neuroscience and Healthcare ETF (IBRN) offers targeted exposure to companies poised to benefit from advancements in neuroscience. With an expense ratio of 0.47%, IBRN provides access to a concentrated portfolio of 57 U.S. and non-U.S. companies. The fund has approximately $0.00B in assets under management and focuses exclusively on the healthcare sector, differentiating it from broader healthcare ETFs. Past performance does not guarantee future results.
ETF Overview
The iShares Neuroscience and Healthcare ETF seeks to track the investment results of an index composed of U.S. and non-U.S. companies that could benefit from the growth and innovation in neuroscience.
IBRN aims to track the investment results of an index composed of companies involved in neuroscience and healthcare innovation. This ETF provides focused exposure to a niche segment within the healthcare sector, targeting companies that are actively involved in research, development, and commercialization of neuroscience-related products and services. The fund's top holdings include Praxis Precision Medicines Inc (5.61%), Axsome Therapeutics Inc (4.53%), and Biogen Inc (4.36%), reflecting a significant allocation to specialized pharmaceutical and biotechnology firms. With 100% of its assets allocated to the healthcare sector, IBRN offers a concentrated bet on the growth potential of neuroscience. The fund's country exposure is primarily to the United States (68.9%), followed by Canada (5.7%) and Ireland (4.5%). IBRN is suitable for investors seeking targeted exposure to the neuroscience sub-sector within healthcare. Past performance does not guarantee future results.
Risk Metrics
IBRN presents several risk considerations for investors. The fund's concentrated sector allocation (100% in healthcare) exposes it to sector-specific risks, such as regulatory changes, clinical trial failures, and shifts in healthcare policy. With 57 holdings, the fund is less diversified than broader market ETFs, increasing the impact of individual stock performance on the overall portfolio. The fund's beta of 1.20 indicates higher volatility compared to the broader market. The expense ratio of 0.47% will create a drag on performance over time. Investors should carefully consider their risk tolerance and investment objectives before investing in IBRN. Past performance does not guarantee future results.
The iShares Neuroscience and Healthcare ETF (IBRN) seeks to track the investment results of an index composed of U.S. and non-U.S. companies that could benefit from the growth and innovation in neuroscience. This means the fund invests in companies involved in the research, development, and commercialization of treatments and technologies related to neurological disorders and brain health. IBRN provides investors with targeted exposure to this specific area within the broader healthcare sector. The fund's holdings are selected based on their potential to benefit from advancements in neuroscience, offering a focused investment strategy.
What is the expense ratio for IBRN?
The expense ratio for IBRN is 0.47%. This means that for every $10,000 invested in the fund, $47 is used to cover the fund's operating expenses annually. While this is a cost to consider, it's important to weigh it against the potential benefits of the fund's targeted investment strategy. When compared to the average expense ratio for equity ETFs, IBRN's expense ratio is slightly higher.
What are the top holdings in IBRN?
The top holdings in IBRN, as of 2026-03-15, include Praxis Precision Medicines Inc (5.61%), Axsome Therapeutics Inc (4.53%), and Biogen Inc (4.36%). Alkermes PLC (4.21%) and Supernus Pharmaceuticals Inc (4.07%) also rank among the fund's largest allocations. These companies represent a significant portion of IBRN's portfolio and reflect the fund's focus on neuroscience and healthcare innovation. These holdings are primarily in the pharmaceutical and biotechnology industries.
Is IBRN a good long-term investment?
Determining whether IBRN is a suitable long-term investment depends on an individual's investment goals, risk tolerance, and time horizon. IBRN offers targeted exposure to the neuroscience and healthcare sector, which may present growth opportunities but also involves specific risks. The fund's beta of 1.20 suggests higher volatility compared to the broader market. Investors should carefully evaluate the fund's investment strategy, expense ratio, and risk profile before making a decision. Past performance does not guarantee future results.
How does IBRN compare to similar ETFs?
IBRN differentiates itself through its specific focus on neuroscience and healthcare innovation. While other healthcare ETFs may offer broader exposure to the healthcare sector, IBRN targets companies directly involved in neuroscience-related activities. The fund's expense ratio of 0.47% is comparable to other specialized ETFs. With approximately $0.00B in AUM, IBRN is smaller than some of the larger, more established healthcare ETFs, which could impact liquidity and trading volume. Investors should compare IBRN's holdings and investment strategy to those of other healthcare ETFs to determine the best fit for their portfolio.
Does IBRN pay dividends?
As of 2026-03-15, IBRN has a dividend yield of 0.00%. This indicates that the fund does not currently distribute dividends to its shareholders. Investors seeking income-generating investments may want to consider other ETFs with a higher dividend yield. The fund's focus is primarily on capital appreciation through investments in growth-oriented companies within the neuroscience and healthcare sector.